Incyte's Povorcitinib Shows Strong Long-Term Efficacy in Hidradenitis Suppurativa Trials

Event summary

  • Incyte presented 54-week data from the STOP-HS Phase 3 trials for povorcitinib, showing durable efficacy in moderate to severe hidradenitis suppurativa (HS) patients.
  • Up to 71.4% of patients achieved HiSCR50, with significant improvements in skin pain, fatigue, and quality of life metrics.
  • The safety profile was consistent with previous 24-week data, with low rates of serious adverse events.
  • Incyte has submitted regulatory applications for povorcitinib in the U.S. and Europe, with decisions pending.

The big picture

Incyte's positive long-term data for povorcitinib positions the drug as a potential first oral treatment option for moderate to severe HS, a condition with significant unmet needs. The results underscore the growing role of JAK inhibitors in dermatology and the strategic shift towards oral therapies in inflammatory skin diseases. Success in HS could pave the way for povorcitinib's expansion into other immune-mediated conditions, strengthening Incyte's inflammation and autoimmunity franchise.

What we're watching

Regulatory Approval
Whether the FDA and EMA will approve povorcitinib based on the submitted data and the upcoming 54-week results.
Market Positioning
How povorcitinib will compete against existing injectable treatments for HS if approved, given its oral administration advantage.
Pipeline Progress
The timeline and potential success of povorcitinib in other indications like vitiligo and prurigo nodularis, with topline data expected in 2026.